SpringWorks Therapeutics (SWTX) Osake Kurssi

SpringWorks Therapeutics Inc is primarily active in the pharmaceutical and biotechnology industries.

The main competitors of SpringWorks Therapeutics Inc in the market include companies like Novartis, Pfizer, and Roche.

SpringWorks Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing life-changing therapies for patients with severe rare diseases and cancer. Founded in 2017, SpringWorks Therapeutics is committed to delivering innovative treatments by leveraging its strategic collaborations and advanced drug development expertise. With a diverse pipeline of investigational therapies, the company aims to address unmet medical needs and improve patients' lives globally. SpringWorks Therapeutics Inc has made significant progress in its mission to transform the lives of patients through its dedication to scientific excellence and groundbreaking research in the field of precision medicine.

Some significant milestones achieved by SpringWorks Therapeutics Inc include the approval of their lead product candidate, Nirogacestat, for the treatment of desmoid tumors by the U.S. FDA. The company also received Fast Track and Orphan Drug designations for Nirogacestat, which further highlights its potential in addressing unmet medical needs. Additionally, SpringWorks Therapeutics Inc has successfully initiated multiple clinical trials evaluating various therapies for rare cancers and genetic diseases. These accomplishments demonstrate the company's commitment towards advancing innovative treatments and improving patients' lives.

SpringWorks Therapeutics Inc is primarily present in the United States.

SpringWorks Therapeutics Inc is a biopharmaceutical company focused on developing innovative therapies for patients with severe rare diseases and cancer. The company's core values include dedication, integrity, and collaboration in their pursuit of discovering novel treatments. With a patient-centric approach, SpringWorks Therapeutics aims to improve the lives of individuals affected by these debilitating conditions. They prioritize scientific excellence and ethical practices to deliver safe and effective therapies. Through strategic partnerships and pioneering research, the company strives to bring hope and transformative solutions to patients in need. SpringWorks Therapeutics Inc is committed to making a lasting impact in the lives of patients and their families.

Analyytikot asettavat tällä hetkellä SpringWorks Therapeutics-osakkeelle keskimääräisen tavoitehinnan 53,33 USD (mediaani: 47,94 USD), mikä merkitsee +13,5 % viimeisimpään hintaan verrattuna. Konsensus perustuu 11 analyytikkoarvioon.

SpringWorks Therapeutics Analyytikkojen kursstavoitteet 2026

11 analyytikkoa arvioi tällä hetkellä SpringWorks Therapeutics-osaketta: 0 suosittaa ostoa, 8 pitoa ja 3 myyntiä. Vuodelle 2026 analyytikot odottavat SpringWorks Therapeutics-yhtiöltä 612,33 M USD liikevaihtoa ja −0,84 USD osakekohtaista tulosta.

SpringWorks Therapeutics Analyytikkojen kursstavoitteet 2026

Nykyisellä valuuttakurssilla SpringWorks Therapeutics-osake noteerataan hintaan 41,93 EUR (46,99 USD).

SpringWorks Therapeutics-osake (SWTX) on listattuna 1 pörssissä, muun muassa: NASDAQ (SWTX).

SpringWorks Therapeutics is a biopharmaceutical company focused on developing therapeutics for patients with rare severe diseases. The business model involves developing innovative therapies with high medical necessity and making them accessible to the market. The company specializes in three main areas: oncology, inherited metabolic disorders, and neurological disorders. SpringWorks aims to develop new and effective therapies for each of these diseases. In the oncology sector, SpringWorks utilizes its expertise in drug discovery and development to create innovative cancer therapies. One of the leading products is Nirogacestat, a Notch pathway inhibitor that has the potential to be used against solid tumors that do not respond to other forms of therapy. In the inherited metabolic disorders division, SpringWorks is working on developing therapies for patients with rare diseases such as Niemann-Pick Type C syndrome. The company has partnered with Cydan Development, a company specializing in developing drugs for rare genetic disorders, for this purpose. In the field of neurological disorders, SpringWorks aims to develop therapies for patients with rare genetic diseases such as epilepsy and Huntington's disease. The company has initiated a collaboration with the Hospital for Sick Children in Toronto for this purpose. The company also has an innovative technology called "Biomarker Relocation" which allows for the identification of patients with certain rare diseases that are otherwise difficult to diagnose and treat. The technology is currently a significant component of SpringWorks' research and development efforts. In recent years, the company has raised capital through investments and collaborations for its business model. The funding has been based on venture capital from leading companies including Novartis Venture Fund, Pfizer Ventures, and OrbiMed. SpringWorks' business strategy also includes partnerships with other companies and research institutions. One collaboration, for example, exists with the Memorial Sloan Kettering Cancer Center, a leading institution in cancer research. The vision of SpringWorks is to play a leading role in the development of therapeutics for patients with rare diseases and to meet the medical need in this area. The company strives to improve the lives of patients with rare diseases and provide them with an optimal medication that alleviates their condition and enhances their quality of life. Overall, SpringWorks is an emerging player in the biotech industry, developing innovative therapeutics to address the needs of patients with rare diseases. With a presence in multiple medical specialties and a strong financing base, the company is poised to secure a position at the forefront of the biotech industry.

odotettu liikevaihto SpringWorks Therapeutics on 612,33 M USD. Tämä luku perustuu nykyisiin talousarvoihin ja heijastaa yhtiön liiketoimintasuoritusta.

odotettu voitto SpringWorks Therapeutics on −62,17 M USD. Nettovoitto kuvastaa yhtiön kannattavuutta kaikkien kulujen vähentämisen jälkeen.

SpringWorks Therapeutics:n hinta-voitto-suhde (P/E) on tällä hetkellä −56,03. P/E-suhde vertaa nykyistä osakekurssia osakekohtaiseen tulokseen ja auttaa sijoittajia arvioimaan SpringWorks Therapeutics-osakkeen arvostusta.

SpringWorks Therapeutics:n hinta-myynti-suhde (P/S) on tällä hetkellä 5,69. P/S-suhde vertaa markkina-arvoa vuosittaisiin tuloihin ja toimii SpringWorks Therapeutics-osakkeen arvostuskennuslukuna.

SpringWorks Therapeutics:n Eulpool-laatuscore on 3/10.

SpringWorks Therapeutics:n ISIN on US85205L1070. ISIN (International Securities Identification Number) on maailmanlaajuisesti ainutlaatuinen arvopaperin tunnus.

SpringWorks Therapeutics:n WKN on A2PRLN. WKN (Wertpapierkennnummer) on kuusinumeroinen saksalainen arvopaperin tunnus.

SpringWorks Therapeutics:n ticker on SWTX. Tämä pörssinoteeraus käytetään SpringWorks Therapeutics-osakkeiden kauppaan pörssissä.